US2005244331A1PendingUtilityA1

Labeled adenosine for use in positron emission tomography

49
Individually held — no corporate assignee on recordPriority: May 22, 2002Filed: Nov 22, 2004Published: Nov 3, 2005
Est. expiryMay 22, 2022(expired)· nominal 20-yr term from priority
Inventors:Edward Abraham
C07H 19/04A61K 51/0491
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Radiolabeled adenosine or radiolabeled adenosine containing molecules for use in positron emission tomography for assessing alterations in adenylate metabolism in a patient are provided.

Claims

exact text as granted — not AI-modified
1 . A positron emission tomography imaging agent comprising radiolabeled adenine or a radiolabeled adenine containing molecule.  
   
   
       2 . The positron emission tomography imaging agent of  claim 1  wherein the adenine or adenine containing molecule is radiolabeled with  11 C,  18 F or  13 NH 2 .  
   
   
       3 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient radiolabeled adenine or a radiolabeled adenine containing molecule and tracing biodistribution of the radiolabeled adenine or radiolabeled adenine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       4 . A compound comprising an  18 F-labeled adenine group.  
   
   
       5 . The compound of  claim 4  wherein the compound comprises a 2- 18 F-labeled adenine group.  
   
   
       6 . The compound of  claim 4  wherein the  18 F-labeled adenine group is selected from the group consisting of 2- 18 F-Adenine, 2- 18 F-adenosine, 2- 18 F-AMP, 2- 18 F-ADP, and 2- 18 F-ATP wherein the label is on the adenine group.  
   
   
       7 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 4  and tracing biodistribution of the radiolabeled adenine or radiolabeled adenine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       8 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 5  and tracing biodistribution of the radiolabeled adenine or radiolabeled adenine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       9 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 6  and tracing biodistribution of the radiolabeled adenine or radiolabeled adenine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       10 . A compound comprising an  11 C-labeled adenine group or an  11 C-labeled adenosine group.  
   
   
       11 . The compound of  claim 4  wherein the  11 C-labeled adenine group is a 2- 11 C-labeled adenine group or a 2- 11 C-labeled adenosine group.  
   
   
       12 . The compound of  claim 4  wherein the  11 C-labeled adenine group is selected fro the group consisting of 2- 11 C-Adenine, 2- 11 C-adenosine, 2- 11 C deoxyadenosine 2- 11 C-AMP, 2- 11 C-ADP, and 2- 11 C-ATP.  
   
   
       13 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 8  and tracing biodistribution of the radiolabeled adenine, radiolabeled adenosine or radiolabeled adenosine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       14 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 9  and tracing biodistribution of the radiolabeled adenine, radiolabeled adenosine or radiolabeled adenosine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.  
   
   
       15 . A method of assessing alterations in adenylate metabolism in a patient comprising administering to the patient the compound of  claim 10  and tracing biodistribution of the radiolabeled adenine, radiolabeled adenosine or radiolabeled adenosine containing molecule by positron emission tomography so that alterations in adenylate metabolism in the patient can be assessed.

Join the waitlist — get patent alerts

Track US2005244331A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.